# The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

> **NCT06281470** · PHASE1 · COMPLETED · sponsor: **Waterstone Pharmaceutical (Wuhan) Co., LTD.** · enrollment: 66 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** WS016 Single Dose(6g)
- **DRUG:** WS016 Single Dose(12g)
- **DRUG:** WS016 Single Dose(24g)
- **DRUG:** WS016 Single Dose(36g)
- **DRUG:** WS016 Single Dose(48g)
- **DRUG:** SAD matching placebo
- **DRUG:** WS016 Multiple Dose(12g)
- **DRUG:** WS016 Multiple Dose(24g)
- **DRUG:** WS016 Multiple Dose(48g)
- **DRUG:** MAD matching placebo

## Key facts

- **NCT ID:** NCT06281470
- **Lead sponsor:** Waterstone Pharmaceutical (Wuhan) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-13
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281470, "The Safety and Tolerability of WS016 in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06281470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*